The IPO market saw an uptick in activity this past week with six IPOs raising $919 million, led by IoT solutions developer Samsara (IOT). 14 SPACs also went public. The pipeline got a boost, with six IPOs and three SPACs submitting...read more
Genenta Science, an Italian Phase 1/2 biotech developing stem cell gene therapies for solid tumors, raised $36 million by offering 3.1 million ADS equivalents, including 0.7 million offered exclusively to existing shareholders in Italy, at $11.50, within the...read more
Genenta Science, an Italian Phase 1/2 biotech developing stem cell gene therapies for solid tumors, announced terms for its IPO on Wednesday. The Milan, Italy-based company plans to raise $30 million by offering 2.6 million ADS equivalents, including 1...read more
Genenta Science, an Italian Phase 1/2 biotech developing stem cell gene therapies for solid tumors, filed on Wednesday with the SEC to raise up to $35 million in an initial public offering. Genenta is engaged in the development of hematopoietic stem cell gene...read more
US IPO Weekly Recap: 6 IPOs debut ahead of the shortened holiday week
The IPO market saw an uptick in activity this past week with six IPOs raising $919 million, led by IoT solutions developer Samsara (IOT). 14 SPACs also went public. The pipeline got a boost, with six IPOs and three SPACs submitting...read more
Italian solid tumor biotech Genenta Science prices upsized US IPO at $11.50 midpoint
Genenta Science, an Italian Phase 1/2 biotech developing stem cell gene therapies for solid tumors, raised $36 million by offering 3.1 million ADS equivalents, including 0.7 million offered exclusively to existing shareholders in Italy, at $11.50, within the...read more
Italian solid tumor biotech Genenta Science sets terms for $30 million US IPO
Genenta Science, an Italian Phase 1/2 biotech developing stem cell gene therapies for solid tumors, announced terms for its IPO on Wednesday. The Milan, Italy-based company plans to raise $30 million by offering 2.6 million ADS equivalents, including 1...read more
Italian solid tumor biotech Genenta Science files for a $35 million US IPO
Genenta Science, an Italian Phase 1/2 biotech developing stem cell gene therapies for solid tumors, filed on Wednesday with the SEC to raise up to $35 million in an initial public offering. Genenta is engaged in the development of hematopoietic stem cell gene...read more